Mode
Text Size
Log in / Sign up
N/A N=548 Randomized Double-blind Treatment

Clinical Study of Approved and Investigational Contact Lenses

Visual Acuity

Enrolled (actual)
548
Serious AEs
0.2%
Results posted
Nov 2016
Primary outcome: Primary: Subjective Overall Comfort Composite Score — 65.17; 68.58; 66.45; 65.46 average clue score

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Senofilcon C Contact Lens (Device); Comfilcon A Contact Lens (Device); Lotrafilcon B Contact Lens (Device); Samfilcon A Contact Lens (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Johnson & Johnson Vision Care, Inc.
Primary completion
Mar 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Subjective Overall Comfort Composite Score
65.17; 68.58; 66.45; 65.46; 66.65; 62.11
PRIMARY
Overall Comfort Individual Item
78; 82; 80; 77; 79.1; 50.7
PRIMARY
Comfort at the End of the Day Individual Item
57.5; 64.6; 60.9; 64.0; 64.2; 47.0
PRIMARY
Comfort Each and Everyday Individual Item
73.2; 76.1; 78.3; 76.5; 79.1; 59.2
PRIMARY
Frequency of Lens Awareness Individual Item
73.2; 74.5; 77.4; 75.8; 75.4; 61.6
PRIMARY
Frequency of Experiencing Dryness Individual Item
62.7; 67.7; 71.4; 67.6; 67.9; 62.5
PRIMARY
Making Your Eyes Feel Moist Throughout the Day Individual Item
68.6; 52.3; 43.7; 55.2; 58.6; 52.3
SECONDARY
Subjective Overall Quality of Vision Composite Score
63.79; 63.31; 64.12; 62.34; 69.45; 68.96
SECONDARY
Overall Quality of Vision Individual Item
82.9; 86.9; 91.0; 84.5; 89.5; 77.7
SECONDARY
Overall Opinion Individual Item
85.8; 73.8; 60.9; 80.9; 75.4; 49.3

Summary

This is a multi-site, 5-visit, double-masked, dispensing study comparing an investigational contact lens with currently-marketed contact lenses. The objective of the study is to evaluate the comfort of the lenses when worn for 30 (-2/+6) days on daily wear modality.

Eligibility Criteria

Inclusion Criteria

  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • The subject must be between 18 to 40 years of age at the time of consent.
  • The subject's spherical equivalent distance refraction must be in the range of -1.25 to -6.00 in each eye.
  • The subject's refractive cylinder must be ≤1.00D in each eye.
  • The subject must have best corrected visual acuity of 20/30 or better in each eye.
  • The subject must be a habitual frequent replacement (reusable) daily wear spherical silicone hydrogel soft contact lens wearer in both eyes.
  • The subject must be able to wear contact lenses for a minimum of 8 hours, 4 days per week.
  • The subject must have normal eyes (i.e., no ocular medications or infections of any type).

Exclusion Criteria

  • Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
  • Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
  • Any known sensitive/allergic to Ingredients of OPTI-FREE® PureMoist® solution.
  • Any daily disposable, extended wear, monovision, toric or multi-focal contact lens correction.
  • Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion.
  • Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.)
  • Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
  • History of binocular vision abnormality or strabismus.
  • Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV), by self-report).
  • Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02708524). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search